For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts
Oneindia App Download

In Bhubaneswar, 3rd phase of COVID-19 vaccine trials to commence soon

|
Google Oneindia News

Bhubaneswar, Oct 27: The third phase of the human trial of the indigenous vaccine against COVID-19, COVAXIN, will commence at a private hospital here soon, an official said.

The search for a suitable vaccine for COVID-19 has almost come to the final stage, Dr E Venkata Rao, Principal Investigator in the COVAXIN human trial and Professor in the department of Community Medicine at the Institute of Medical Sciences and SUM Hospital here said on Sunday.

In Bhubaneswar, 3rd phase of COVID-19 vaccine trials to commence soon

IMS and SUM Hospital is among the 21 medical institutes selected across the country by the Indian Council for Medical Research (ICMR) where the third phase trial would be conducted.

 Bharat Biotech's COVID-19 vaccine Covaxin gets approval for phase 3 trials Bharat Biotech's COVID-19 vaccine Covaxin gets approval for phase 3 trials

The indigenous vaccine, being developed by ICMR and Bharat Biotech has received the approval of the Central Drugs Standard Control Organisation (CDSCO) for initiating the third phase trial. After completion of the first and second phase of the trial with demonstrable safety profile and immunogenicity, the large-scale efficacy trial involving thousands of volunteers has been planned now, Dr Rao said.

Dr Rao, who is the head of the Preventive and Therapeutic Clinical Trial Unit (PTCTU), said during this phase the age limit and eligibility/ screening criteria would be relaxed and several volunteers who are otherwise apparently healthy would be recruited for the trial.

Like the previous phases, half of the volunteers would receive a placebo and the remaining half would be administered COVAXIN in this phase. Even health care workers would be recruited for the trial. The volunteers would be followed up over a considerable period of time to look at the efficacy of the vaccine in preventing the development of the Corona disease, he said.

Covaxin to use ViroVax's adjuvant Alhydroxiquim-II to boost immune responseCovaxin to use ViroVax's adjuvant Alhydroxiquim-II to boost immune response

Rao said there had been a huge response and enthusiasm among people who had offered themselves to be volunteers for the trial. He said persons above 18 years will be taken for the human trial.

Recommended Video

Coronavirus Pandemic: Oxford Covid Vaccine brings hope for the elderly | Oneindia News

The interested volunteers for the project could enroll themselves for the trial by registering online at www.ptctu.soa.ac under the section register for clinical trials, he said.

For Daily Alerts
Get Instant News Updates
Enable
x
Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
X